Navigation Links
Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Date:4/10/2013

WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting.  The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide range of solid tumors.

"The results presented at the AACR Annual Meeting demonstrate that NovoTTF Therapy inhibits the growth of squamous histology non-small cell lung cancer as well as pancreatic and ovarian cancers in preclinical models," said Eilon Kirson , M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.  "We intend to build on this research through clinical trials evaluating the efficacy of NovoTTF Therapy in these indications when delivered in combination with chemotherapy."

AACR Annual Meeting 2013 Abstracts

  • Giladi et al, Development of an orthotopic squamous cell carcinoma (SCC) lung cancer model.  Data were presented describing a new in vivo model to test the efficacy of anti-neoplastic treatments in SCC lung cancer.  Abstract #340.
  • Giladi et al, NovoTTF Therapy inhibited the growth of pancreatic and ovarian cancer in vitro. Additionally, the data supports a conclusion that modulation of NovoTTF Therapy frequency may overcome treatment resistance. Abstract #5569.

About NovoTTF Therapy
NovoTTF Therapy is delivered by portable, non-invasive medical devices designed for continuous use throughout the day by the patient. NovoTTF Therapy has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The delivery systems weigh about six pounds and create a low intensity, alternati
'/>"/>

SOURCE Novocure
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
4. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
5. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
6. Cardium Presents Year-End 2012 Financial Results And Recent Developments
7. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
8. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
9. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
10. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
11. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... ultra rapid acting insulin presented at the American Diabetes ... ORLEANS, June 6 /PRNewswire-FirstCall/ -- ... investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA ... to standard of care therapies in controlling post-meal blood ...
... June 6 Boehringer Ingelheim Pharmaceuticals, Inc. today announced ... the type 2 diabetes therapeutic area. The Company ... clinical development worldwide. New Phase II data results ... inhibitor and the Company,s lead diabetes compound, were presented ...
Cached Medicine Technology:Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 2Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 3Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... ER visits and additional imaging services , CHICAGO, ... quickly could cut by half the amount paid for hospital ... Clinical Congress of the American College of Surgeons. According to ... gallstones at the University of North Carolina in 2008, the ...
... onerous, futile medical interventions are ordered for these end-stage ... -- Many people see end-stage dementia as affecting only ... disease,s effects are far-reaching and eventually fatal. , ... not a terminal condition can have negative ...
... ... organization (PPO) plans in Albany, Essex, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties, ... Medicare Choices individual PPO plans now serve Medicare-eligibles in 23 counties, while its group ... ...
... between brain and device , WEDNESDAY, Oct. 14 (HealthDay ... connections between prosthetic hands and the brain, potentially paving ... type, sense hot and cold, and touch others. , ... "would allow people to have a prosthetic that functions ...
... 14 The National Women,s Law Center,s (NWLC) groundbreaking ... Health Insurance Market Fails Women," first released in ... discriminates against women. Now, this ground-breaking research has resulted ... signed by Governor Schwarzenegger over the weekend -- that ...
... Oct. 14 The Guardian Life Insurance Company of America ... leading provider of employee and voluntary benefits for small and ... products and their sales force according to a study conducted ... that Guardian received "very good to excellent" ratings on all ...
Cached Medicine News:Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 2Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 3Health News:Families Need to Know When Dementia Becomes Terminal 2Health News:Families Need to Know When Dementia Becomes Terminal 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 2Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 4Health News:Fine-Tuning Prosthetic Hands to Restore a Sense of Touch 2Health News:National Women's Law Center Challenges Insurance Industry Practices That Treat Being a Woman Like a 'Pre-Existing Condition' 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 3
... identified in 1980 (1) and has only recently ... (2). PYY is produced by the gut and ... is found to decrease appetite. The main form ... is PYY3-36, the N-terminal truncated form of the ...
... Human sex hormone-binding globulin (SHBG) is ... steroids with relatively high specificity and low ... bound to SHBG) and, to a much ... C18 and C19 steroid structures and regulates ...
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
Medicine Products: